Innovation Pharmaceuticals Inc (IPIX)

[Whoops]

Brilacidin for ABSSSI should fetch a much higher price than Dalvance. Dalvance is a remake drug that went up against Vancomycin data from two of studies:
Trial 1: Dalvance: 83.3% and Vancomycin/Linezolid: 81.8%; Trial 2: Dalvance: 76.8% and Vancomycin/Linezolid: 78.3%.

Now recall the numbers from Brilacidin 2a efficacy no#s: 87%, 92.6% and 83.3% with the comparison being made to top of the line Daptomycin.

https://www.centerwatch.com/drug-information/fda-approved-drugs/drug/1329/dalvance-dalbavancin

http://files.shareholder.com/downloads/ABEA-4ITCYZ/1997024712x0x611205/FEA66C67-D02F-4FF2-B230-AA711F46ED7F/PMX-30063_Antibiotic_Fact_Sheet_Nov_2012_.pdf